Haas Jennifer S, Sprague Brian L, Klabunde Carrie N, Tosteson Anna N A, Chen Jane S, Bitton Asaf, Beaber Elisabeth F, Onega Tracy, Kim Jane J, MacLean Charles D, Harris Kimberly, Yamartino Phillip, Howe Kathleen, Pearson Loretta, Feldman Sarah, Brawarsky Phyllis, Schapira Marilyn M
Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
J Gen Intern Med. 2016 Jan;31(1):52-9. doi: 10.1007/s11606-015-3449-5.
Changes to national guidelines for breast and cervical cancer screening have created confusion and controversy for women and their primary care providers.
To characterize women's primary health care provider attitudes towards screening and changes in practice in response to recent revisions in guidelines for breast and cervical cancer screening.
DESIGN, SETTING, PARTICIPANTS: In 2014, we distributed a confidential web and mail survey to 668 women's health care providers affiliated with the four clinical care networks participating in the three PROSPR (Population-based Research Optimizing Screening through Personalized Regimens) consortium breast cancer research centers (385 respondents; response rate 57.6 %).
We assessed self-reported attitudes toward breast and cervical cancer screening, as well as practice changes in response to the most recent revisions of the U.S. Preventive Services Task Force (USPSTF) recommendations.
The majority of providers believed that mammography screening was effective for reducing cancer mortality among women ages 40-74 years, and that Papanicolaou (Pap) testing was very effective for women ages 21-64 years. While the USPSTF breast and cervical cancer screening recommendations were widely perceived by the respondents as influential, 75.7 and 41.2 % of providers (for mammography and cervical cancer screening, respectively) reported screening practices in excess of those recommended by USPSTF. Provider-reported barriers to concordance with guideline recommendations included: patient concerns (74 and 36 % for breast and cervical, respectively), provider disagreement with the recommendations (50 and 14 %), health system measurement of a provider's screening practices that use conflicting measurement criteria (40 and 21 %), concern about malpractice risk (33 and 11 %), and lack of time to discuss the benefits and harms with their patients (17 and 8 %).
Primary care providers do not consistently follow recent USPSTF breast and cervical cancer screening recommendations, despite noting that these guidelines are influential.
国家乳腺癌和宫颈癌筛查指南的变更给女性及其初级保健提供者带来了困惑和争议。
描述女性初级保健提供者对筛查的态度以及因近期乳腺癌和宫颈癌筛查指南修订而在实践中的变化。
设计、地点、参与者:2014年,我们向隶属于参与三个PROSPR(通过个性化方案优化基于人群的筛查研究)联盟乳腺癌研究中心的四个临床护理网络的668名女性医疗保健提供者分发了一份保密的网络和邮件调查问卷(385名受访者;回复率57.6%)。
我们评估了自我报告的对乳腺癌和宫颈癌筛查的态度,以及因美国预防服务工作组(USPSTF)建议的最新修订而在实践中的变化。
大多数提供者认为,乳腺钼靶筛查对降低40 - 74岁女性的癌症死亡率有效,而巴氏试验对21 - 64岁女性非常有效。虽然受访者普遍认为USPSTF乳腺癌和宫颈癌筛查建议具有影响力,但分别有75.7%和41.2%的提供者(针对乳腺钼靶和宫颈癌筛查)报告其筛查实践超出了USPSTF的建议。提供者报告的与指南建议不一致的障碍包括:患者担忧(乳腺癌和宫颈癌分别为74%和36%)、提供者不同意这些建议(50%和14%)、卫生系统对使用相互冲突的测量标准的提供者筛查实践进行测量(40%和21%)、担心医疗事故风险(33%和11%)以及缺乏时间与患者讨论利弊(17%和8%)。
尽管注意到这些指南具有影响力,但初级保健提供者并未始终遵循USPSTF最近的乳腺癌和宫颈癌筛查建议。